Unraveling the Role of ACE2, the Binding Receptor for SARS-CoV-2, in Inflammatory Bowel Disease. Issue 12 (16th October 2020)

• Record Type: Journal Article
• Authors: Ferreira-Duarte, Mariana; Estevinho, Maria Manuela; Duarte-Araújo, Margarida; Magro, Fernando; Morato, Manuela
• Is Part Of: Inflammatory bowel diseases. Volume 26:Issue 12(2020)
• Page Start: 1787
• Page End: 1795
• Publication Date: 2020-10-16
• Subjects: inflammatory bowel disease -- IBD -- angiotensin-converting enzyme 2 -- SARS-CoV-2 receptor -- tryptophan absorption -- integrin signaling; Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1093/ibd/izaa249
• Languages: English
• ISSNs: 1078-0998

Abstract

Abstract: Angiotensin-converting enzyme 2 (ACE2) has been highlighted for its role as a receptor for SARS-CoV-2, responsible for the current COVID-19 pandemic. This review summarizes current knowledge about ACE2 as a multifunctional protein, focusing on its relevance in inflammatory bowel disease (IBD). As an enzyme, ACE2 may be protective in IBD because it favors the counter-regulatory arm of the renin-angiotensin system or deleterious because it metabolizes other anti-inflammatory/repairing elements. Meanwhile, as a receptor for SARS-CoV-2, the impact of ACE2 expression/activity on infection is still under debate because no direct evidence has been reported and, again, both protective and deleterious pathways are possible. Research has shown that ACE2 regulates the expression of the neutral amino acid transporter B 0 AT1, controlling tryptophan-associated intestinal inflammation and nutritional status. Finally, intact membrane-bound or shed soluble ACE2 can also trigger integrin signaling, modulating the response to anti-integrin biologic drugs used to treat IBD (such as vedolizumab) and fibrosis, a long-term complication of IBD. As such, future studies on ACE2 expression/activity in IBD can improve monitoring of the disease and explore an alternative pharmacological target.